FierceBiotechFierceBioResearcherFierceBiotechITFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Innovative vaccines get EMEA panel approval

  • Email
  • Print
  • Comment
  • Contact Author
  • Reprint

Baxter International's H5N1 flu vaccine, Celvapan, received CHMP approval last week, meaning the vaccine could become the first cell culture-based H5N1 influenza vax to hit the market. Celvapan is grown in monkey kidney cells. Sanofi Pasteur and GlaxoSmithKline currently have two egg-based vaccines on the market. The cell-based method is faster than the egg-based approach because the virus used in the vaccine does not required modification to grow in chicken eggs, Baxter tells the Center for Infectious Disease Research and Policy.

Sanofi Pasteur also snagged a CHMP recommendation for Intanza, a seasonal flu vaccine that is injected below intradermally, rather than into muscle--the first of its kind to be approved by the CHMP. The application, submitted back in February, was based on clinical trials involving more than 7,000 adult and elderly participants. In a Phase III trial, Intanza induced a stronger immune response when given intradermally than intramuscularly, Susan Watkins, a Sanofi spokeswoman tells the CIDRAP.

- view the Baxter release
- check out the Sanofi release
- read the CIDRAP for more

Related Articles:
Cell-based pandemic vaccine successful in human trial
Baxter, GSK sign UK pandemic vaccine deal (Sept 2007)
Sanofi Pasteur begins melanoma vaccine trial
Combo vaccines endorsed by federal advisory panel
Sanofi licenses technology for new TB vaccine

More stories about Vaccine   Sanofi Pasteur   Celvapan   Baxter International  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.